Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316779 | 0.90 | USP2 (0.43) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL409841 | 0.89 | USP2 (0.42) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL23347862 | 0.88 | USP2 (0.41) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL22001200 | 0.85 | DRD4 (0.51) | ALDH1A1HTR7HTR1A | |
| SCHEMBL16209774 | 0.83 | HTR7 (0.47) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL22000951 | 0.82 | DRD2 (0.43) | HTR7HTR1ATLR8TLR7TLR9 | |
| SCHEMBL14655016 | 0.82 | USP2 (0.45) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL19981430 | 0.82 | USP2 (0.45) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL16219437 | 0.81 | USP2 (0.47) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL21940903 | 0.81 | TLR9 (0.57) | USP2POLBALDH1A1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | USP2 4607/4885POLB 145/4885ALDH1A1 4394/4885 |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | USP2 4607/4885POLB 145/4885ALDH1A1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.